Ignite Creation Date:
2025-12-25 @ 5:02 AM
Ignite Modification Date:
2026-06-01 @ 2:26 PM
Study NCT ID:
NCT04608318
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-12-31
First Post:
2020-10-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
Sponsor:
Organization: